Global Vaccine Particulate Adjuvants Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
Table of Contents1 Report Overview
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Vaccine Particulate Adjuvants Market Size Growth Rate by Type (2017 VS 2021 VS 2028)
1.2.2 Oral
1.2.3 Subcutaneous
1.2.4 Intranasal
1.2.5 Intramuscular
1.2.6 Intradermal
1.2.7 Others
1.3 Market Segment by Application
1.3.1 Global Vaccine Particulate Adjuvants Market Share by Application (2017 VS 2021 VS 2028)
1.3.2 Infectious Diseases
1.3.3 Cancer
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Vaccine Particulate Adjuvants Market Size (2017-2028)
2.1.1 Global Vaccine Particulate Adjuvants Revenue (2017-2028)
2.1.2 Global Vaccine Particulate Adjuvants Sales (2017-2028)
2.2 Global Vaccine Particulate Adjuvants Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.2.1 Global Vaccine Particulate Adjuvants Sales by Regions (2017-2022)
2.2.2 Global Vaccine Particulate Adjuvants Revenue by Regions (2017-2022)
2.3 Global Vaccine Particulate Adjuvants Market Size Forecast by Region
2.3.1 Global Vaccine Particulate Adjuvants Sales Forecast by Region (2023-2028)
2.3.2 Global Vaccine Particulate Adjuvants Revenue Forecast by Region (2023-2028)
2.4 Global Top Vaccine Particulate Adjuvants Regions (Countries) Ranking by Market Size
2.5 Vaccine Particulate Adjuvants Market Dynamics
2.5.1 Vaccine Particulate Adjuvants Market Trends
2.5.2 Vaccine Particulate Adjuvants Market Drivers
2.5.3 Vaccine Particulate Adjuvants Market Challenges
2.5.4 Vaccine Particulate Adjuvants Market Restraints
3 Competitive Landscape by Manufacturers
3.1 Global Top Vaccine Particulate Adjuvants Manufacturers by Sales (2017-2022)
3.1.1 Global Vaccine Particulate Adjuvants Sales by Manufacturers (2017-2022)
3.1.2 Global Vaccine Particulate Adjuvants Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global 5 and 10 Largest Manufacturers by Vaccine Particulate Adjuvants Sales in 2021
3.2 Global Top Manufacturers Vaccine Particulate Adjuvants by Revenue
3.2.1 Global Vaccine Particulate Adjuvants Revenue by Manufacturers (2017-2022)
3.2.2 Top Vaccine Particulate Adjuvants Manufacturers Covered: Ranking by Revenue
3.2.3 Global Vaccine Particulate Adjuvants Revenue Share by Manufacturers (2017-2022)
3.2.4 Global Vaccine Particulate Adjuvants Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Vaccine Particulate Adjuvants as of 2021)
3.4 Global Vaccine Particulate Adjuvants Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Vaccine Particulate Adjuvants Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Vaccine Particulate Adjuvants Market
3.7 Key Manufacturers Vaccine Particulate Adjuvants Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Vaccine Particulate Adjuvants Market Size by Type
4.1 Global Vaccine Particulate Adjuvants Historic Market Review by Type (2017-2022)
4.1.1 Global Vaccine Particulate Adjuvants Sales Market Share by Type (2017-2022)
4.1.2 Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2017-2022)
4.1.3 Vaccine Particulate Adjuvants Price by Type (2017-2022)
4.2 Global Vaccine Particulate Adjuvants Market Estimates and Forecasts by Type (2023-2028)
4.2.1 Global Vaccine Particulate Adjuvants Sales Forecast by Type (2023-2028)
4.2.2 Global Vaccine Particulate Adjuvants Revenue Forecast by Type (2023-2028)
4.2.3 Vaccine Particulate Adjuvants Price Forecast by Type (2023-2028)
5 Global Vaccine Particulate Adjuvants Market Size by Application
5.1 Global Vaccine Particulate Adjuvants Historic Market Review by Application (2017-2022)
5.1.1 Global Vaccine Particulate Adjuvants Sales Market Share by Application (2017-2022)
5.1.2 Global Vaccine Particulate Adjuvants Revenue Market Share by Application (2017-2022)
5.1.3 Vaccine Particulate Adjuvants Price by Application (2017-2022)
5.2 Global Vaccine Particulate Adjuvants Market Estimates and Forecasts by Application (2023-2028)
5.2.1 Global Vaccine Particulate Adjuvants Sales Forecast by Application (2023-2028)
5.2.2 Global Vaccine Particulate Adjuvants Revenue Forecast by Application (2023-2028)
5.2.3 Vaccine Particulate Adjuvants Price Forecast by Application (2023-2028)
6 North America
6.1 North America Vaccine Particulate Adjuvants Sales Breakdown by Company
6.1.1 North America Vaccine Particulate Adjuvants Sales by Company (2017-2022)
6.1.2 North America Vaccine Particulate Adjuvants Revenue by Company (2017-2022)
6.2 North America Vaccine Particulate Adjuvants Market Size by Type
6.2.1 North America Vaccine Particulate Adjuvants Sales by Type (2017-2028)
6.2.2 North America Vaccine Particulate Adjuvants Revenue by Type (2017-2028)
6.3 North America Vaccine Particulate Adjuvants Market Size by Application
6.3.1 North America Vaccine Particulate Adjuvants Sales by Application (2017-2028)
6.3.2 North America Vaccine Particulate Adjuvants Revenue by Application (2017-2028)
6.4 North America Vaccine Particulate Adjuvants Market Size by Country
6.4.1 North America Vaccine Particulate Adjuvants Sales by Country (2017-2028)
6.4.2 North America Vaccine Particulate Adjuvants Revenue by Country (2017-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Vaccine Particulate Adjuvants Sales Breakdown by Company
7.1.1 Europe Vaccine Particulate Adjuvants Sales by Company (2017-2022)
7.1.2 Europe Vaccine Particulate Adjuvants Revenue by Company (2017-2022)
7.2 Europe Vaccine Particulate Adjuvants Market Size by Type
7.2.1 Europe Vaccine Particulate Adjuvants Sales by Type (2017-2028)
7.2.2 Europe Vaccine Particulate Adjuvants Revenue by Type (2017-2028)
7.3 Europe Vaccine Particulate Adjuvants Market Size by Application
7.3.1 Europe Vaccine Particulate Adjuvants Sales by Application (2017-2028)
7.3.2 Europe Vaccine Particulate Adjuvants Revenue by Application (2017-2028)
7.4 Europe Vaccine Particulate Adjuvants Market Size by Country
7.4.1 Europe Vaccine Particulate Adjuvants Sales by Country (2017-2028)
7.4.2 Europe Vaccine Particulate Adjuvants Revenue by Country (2017-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Vaccine Particulate Adjuvants Sales Breakdown by Company
8.1.1 Asia Pacific Vaccine Particulate Adjuvants Sales by Company (2017-2022)
8.1.2 Asia Pacific Vaccine Particulate Adjuvants Revenue by Company (2017-2022)
8.2 Asia Pacific Vaccine Particulate Adjuvants Market Size by Type
8.2.1 Asia Pacific Vaccine Particulate Adjuvants Sales by Type (2017-2028)
8.2.2 Asia Pacific Vaccine Particulate Adjuvants Revenue by Type (2017-2028)
8.3 Asia Pacific Vaccine Particulate Adjuvants Market Size by Application
8.3.1 Asia Pacific Vaccine Particulate Adjuvants Sales by Application (2017-2028)
8.3.2 Asia Pacific Vaccine Particulate Adjuvants Revenue by Application (2017-2028)
8.4 Asia Pacific Vaccine Particulate Adjuvants Market Size by Region
8.4.1 Asia Pacific Vaccine Particulate Adjuvants Sales by Region
8.4.2 Asia Pacific Vaccine Particulate Adjuvants Revenue by Region
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Vaccine Particulate Adjuvants Sales Breakdown by Company
9.1.1 Latin America Vaccine Particulate Adjuvants Sales by Company (2017-2022)
9.1.2 Latin America Vaccine Particulate Adjuvants Revenue by Company (2017-2022)
9.2 Latin America Vaccine Particulate Adjuvants Market Size by Type
9.2.1 Latin America Vaccine Particulate Adjuvants Sales by Type (2017-2028)
9.2.2 Latin America Vaccine Particulate Adjuvants Revenue by Type (2017-2028)
9.3 Latin America Vaccine Particulate Adjuvants Market Size by Application
9.3.1 Latin America Vaccine Particulate Adjuvants Sales by Application (2017-2028)
9.3.2 Latin America Vaccine Particulate Adjuvants Revenue by Application (2017-2028)
9.4 Latin America Vaccine Particulate Adjuvants Market Size by Country
9.4.1 Latin America Vaccine Particulate Adjuvants Sales by Country (2017-2028)
9.4.2 Latin America Vaccine Particulate Adjuvants Revenue by Country (2017-2028)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Vaccine Particulate Adjuvants Sales Breakdown by Company
10.1.1 Middle East and Africa Vaccine Particulate Adjuvants Sales by Company (2017-2022)
10.1.2 Middle East and Africa Vaccine Particulate Adjuvants Revenue by Company (2017-2022)
10.2 Middle East and Africa Vaccine Particulate Adjuvants Market Size by Type
10.2.1 Middle East and Africa Vaccine Particulate Adjuvants Sales by Type (2017-2028)
10.2.2 Middle East and Africa Vaccine Particulate Adjuvants Revenue by Type (2017-2028)
10.3 Middle East and Africa Vaccine Particulate Adjuvants Market Size by Application
10.3.1 Middle East and Africa Vaccine Particulate Adjuvants Sales by Application (2017-2028)
10.3.2 Middle East and Africa Vaccine Particulate Adjuvants Revenue by Application (2017-2028)
10.4 Middle East and Africa Vaccine Particulate Adjuvants Market Size by Country
10.4.1 Middle East and Africa Vaccine Particulate Adjuvants Sales by Country (2017-2028)
10.4.2 Middle East and Africa Vaccine Particulate Adjuvants Revenue by Country (2017-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 U.A.E
11 Company Profiles
11.1 Brenntag Biosector (Denmark)
11.1.1 Brenntag Biosector (Denmark) Corporation Information
11.1.2 Brenntag Biosector (Denmark) Overview
11.1.3 Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.1.4 Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Products and Services
11.1.5 Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants SWOT Analysis
11.1.6 Brenntag Biosector (Denmark) Recent Developments
11.2 CSL Limited (Australia)
11.2.1 CSL Limited (Australia) Corporation Information
11.2.2 CSL Limited (Australia) Overview
11.2.3 CSL Limited (Australia) Vaccine Particulate Adjuvants Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.2.4 CSL Limited (Australia) Vaccine Particulate Adjuvants Products and Services
11.2.5 CSL Limited (Australia) Vaccine Particulate Adjuvants SWOT Analysis
11.2.6 CSL Limited (Australia) Recent Developments
11.3 SEPPIC (France)
11.3.1 SEPPIC (France) Corporation Information
11.3.2 SEPPIC (France) Overview
11.3.3 SEPPIC (France) Vaccine Particulate Adjuvants Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.3.4 SEPPIC (France) Vaccine Particulate Adjuvants Products and Services
11.3.5 SEPPIC (France) Vaccine Particulate Adjuvants SWOT Analysis
11.3.6 SEPPIC (France) Recent Developments
11.4 Agenus, Inc (US)
11.4.1 Agenus, Inc (US) Corporation Information
11.4.2 Agenus, Inc (US) Overview
11.4.3 Agenus, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.4.4 Agenus, Inc (US) Vaccine Particulate Adjuvants Products and Services
11.4.5 Agenus, Inc (US) Vaccine Particulate Adjuvants SWOT Analysis
11.4.6 Agenus, Inc (US) Recent Developments
11.5 Novavax, Inc (US)
11.5.1 Novavax, Inc (US) Corporation Information
11.5.2 Novavax, Inc (US) Overview
11.5.3 Novavax, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.5.4 Novavax, Inc (US) Vaccine Particulate Adjuvants Products and Services
11.5.5 Novavax, Inc (US) Vaccine Particulate Adjuvants SWOT Analysis
11.5.6 Novavax, Inc (US) Recent Developments
11.6 SPI Pharma, Inc (US)
11.6.1 SPI Pharma, Inc (US) Corporation Information
11.6.2 SPI Pharma, Inc (US) Overview
11.6.3 SPI Pharma, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.6.4 SPI Pharma, Inc (US) Vaccine Particulate Adjuvants Products and Services
11.6.5 SPI Pharma, Inc (US) Vaccine Particulate Adjuvants SWOT Analysis
11.6.6 SPI Pharma, Inc (US) Recent Developments
11.7 Invivogen (US)
11.7.1 Invivogen (US) Corporation Information
11.7.2 Invivogen (US) Overview
11.7.3 Invivogen (US) Vaccine Particulate Adjuvants Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.7.4 Invivogen (US) Vaccine Particulate Adjuvants Products and Services
11.7.5 Invivogen (US) Vaccine Particulate Adjuvants SWOT Analysis
11.7.6 Invivogen (US) Recent Developments
11.8 Avanti Polar Lipids, Inc (US)
11.8.1 Avanti Polar Lipids, Inc (US) Corporation Information
11.8.2 Avanti Polar Lipids, Inc (US) Overview
11.8.3 Avanti Polar Lipids, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.8.4 Avanti Polar Lipids, Inc (US) Vaccine Particulate Adjuvants Products and Services
11.8.5 Avanti Polar Lipids, Inc (US) Vaccine Particulate Adjuvants SWOT Analysis
11.8.6 Avanti Polar Lipids, Inc (US) Recent Developments
11.9 MVP Laboratories, Inc (US)
11.9.1 MVP Laboratories, Inc (US) Corporation Information
11.9.2 MVP Laboratories, Inc (US) Overview
11.9.3 MVP Laboratories, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.9.4 MVP Laboratories, Inc (US) Vaccine Particulate Adjuvants Products and Services
11.9.5 MVP Laboratories, Inc (US) Vaccine Particulate Adjuvants SWOT Analysis
11.9.6 MVP Laboratories, Inc (US) Recent Developments
11.10 OZ Biosciences (France)
11.10.1 OZ Biosciences (France) Corporation Information
11.10.2 OZ Biosciences (France) Overview
11.10.3 OZ Biosciences (France) Vaccine Particulate Adjuvants Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.10.4 OZ Biosciences (France) Vaccine Particulate Adjuvants Products and Services
11.10.5 OZ Biosciences (France) Vaccine Particulate Adjuvants SWOT Analysis
11.10.6 OZ Biosciences (France) Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Vaccine Particulate Adjuvants Value Chain Analysis
12.2 Vaccine Particulate Adjuvants Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Vaccine Particulate Adjuvants Production Mode & Process
12.4 Vaccine Particulate Adjuvants Sales and Marketing
12.4.1 Vaccine Particulate Adjuvants Sales Channels
12.4.2 Vaccine Particulate Adjuvants Distributors
12.5 Vaccine Particulate Adjuvants Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
List of TablesTable 1. Global Vaccine Particulate Adjuvants Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Oral
Table 3. Major Manufacturers of Subcutaneous
Table 4. Major Manufacturers of Intranasal
Table 5. Major Manufacturers of Intramuscular
Table 6. Major Manufacturers of Intradermal
Table 7. Major Manufacturers of Others
Table 8. Global Vaccine Particulate Adjuvants Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 9. Global Vaccine Particulate Adjuvants Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 10. Global Vaccine Particulate Adjuvants Sales by Region (2017-2022) & (K Pcs)
Table 11. Global Vaccine Particulate Adjuvants Sales Market Share by Region (2017-2022)
Table 12. Global Vaccine Particulate Adjuvants Revenue by Region (2017-2022) & (US$ Million)
Table 13. Global Vaccine Particulate Adjuvants Revenue Market Share by Region (2017-2022)
Table 14. Global Vaccine Particulate Adjuvants Sales Forecast by Region (2023-2028) & (K Pcs)
Table 15. Global Vaccine Particulate Adjuvants Sales Market Share Forecast by Region (2023-2028)
Table 16. Global Vaccine Particulate Adjuvants Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 17. Global Vaccine Particulate Adjuvants Revenue Market Share Forecast by Region (2023-2028)
Table 18. Top Vaccine Particulate Adjuvants Regions (Countries) Ranking by Market Size (US$ Million) in 2021
Table 19. Vaccine Particulate Adjuvants Market Trends
Table 20. Vaccine Particulate Adjuvants Market Drivers
Table 21. Vaccine Particulate Adjuvants Market Challenges
Table 22. Vaccine Particulate Adjuvants Market Restraints
Table 23. Global Vaccine Particulate Adjuvants Sales by Manufacturers (2017-2022) & (K Pcs)
Table 24. Global Vaccine Particulate Adjuvants Sales Share by Manufacturers (2017-2022)
Table 25. Global Vaccine Particulate Adjuvants Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 26. Ranking of Global Top Vaccine Particulate Adjuvants Manufacturers by Revenue (US$ Million) in 2021
Table 27. Vaccine Particulate Adjuvants Revenue Share by Manufacturers (2017-2022)
Table 28. Global Vaccine Particulate Adjuvants Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 29. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Vaccine Particulate Adjuvants as of 2021)
Table 30. Key Manufacturers Vaccine Particulate Adjuvants Average Selling Price (ASP) & (2017-2022) & (USD/Pcs)
Table 31. Key Manufacturers Vaccine Particulate Adjuvants Plants/Factories Distribution
Table 32. Key Manufacturers Vaccine Particulate Adjuvants Area Served
Table 33. Date of Key Manufacturers Enter into Vaccine Particulate Adjuvants Market
Table 34. Key Manufacturers Vaccine Particulate Adjuvants Product Type
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Vaccine Particulate Adjuvants Sales (K Pcs) by Type (2017-2022)
Table 37. Global Vaccine Particulate Adjuvants Sales Share by Type (2017-2022)
Table 38. Global Vaccine Particulate Adjuvants Revenue (US$ Million) Market Share by Type (2017-2022)
Table 39. Global Vaccine Particulate Adjuvants Price (K Pcs) by Type (2017-2022)
Table 40. Global Vaccine Particulate Adjuvants Sales (K Pcs) by Type (2023-2028)
Table 41. Global Vaccine Particulate Adjuvants Sales Share by Type (2023-2028)
Table 42. Global Vaccine Particulate Adjuvants Revenue (US$ Million) Market Share by Type (2023-2028)
Table 43. Global Vaccine Particulate Adjuvants Revenue Share by Type (2023-2028)
Table 44. Global Vaccine Particulate Adjuvants Price (K Pcs) by Type (2023-2028)
Table 45. Global Vaccine Particulate Adjuvants Sales (K Pcs) by Application (2017-2022)
Table 46. Global Vaccine Particulate Adjuvants Sales Share by Application (2017-2022)
Table 47. Global Vaccine Particulate Adjuvants Revenue (US$ Million) Market Share by Application (2017-2022)
Table 48. Global Vaccine Particulate Adjuvants Price (K Pcs) by Application (2017-2022)
Table 49. Global Vaccine Particulate Adjuvants Sales (K Pcs) by Application (2023-2028)
Table 50. Global Vaccine Particulate Adjuvants Sales Share by Application (2023-2028)
Table 51. Global Vaccine Particulate Adjuvants Revenue (US$ Million) Market Share by Application (2023-2028)
Table 52. Global Vaccine Particulate Adjuvants Revenue Share by Application (2023-2028)
Table 53. Global Vaccine Particulate Adjuvants Price (K Pcs) by Application (2023-2028)
Table 54. North America Vaccine Particulate Adjuvants Sales by Company (2017-2022) & (K Pcs)
Table 55. North America Vaccine Particulate Adjuvants Sales Market Share by Company (2017-2022)
Table 56. North America Vaccine Particulate Adjuvants Revenue by Company (2017-2022) & (US$ Million)
Table 57. North America Vaccine Particulate Adjuvants Revenue Market Share by Company (2017-2022)
Table 58. North America Vaccine Particulate Adjuvants Sales by Type (2017-2022) & (K Pcs)
Table 59. North America Vaccine Particulate Adjuvants Sales by Type (2023-2028) & (K Pcs)
Table 60. North America Vaccine Particulate Adjuvants Revenue by Type (2017-2022) & (US$ Million)
Table 61. North America Vaccine Particulate Adjuvants Revenue by Type (2023-2028) & (US$ Million)
Table 62. North America Vaccine Particulate Adjuvants Sales by Application (2017-2022) & (K Pcs)
Table 63. North America Vaccine Particulate Adjuvants Sales by Application (2023-2028) & (K Pcs)
Table 64. North America Vaccine Particulate Adjuvants Revenue by Application (2017-2022) & (US$ Million)
Table 65. North America Vaccine Particulate Adjuvants Revenue by Application (2023-2028) & (US$ Million)
Table 66. North America Vaccine Particulate Adjuvants Sales by Country (2017-2022) & (K Pcs)
Table 67. North America Vaccine Particulate Adjuvants Sales by Country (2023-2028) & (K Pcs)
Table 68. North America Vaccine Particulate Adjuvants Revenue by Country (2017-2022) & (US$ Million)
Table 69. North America Vaccine Particulate Adjuvants Revenue by Country (2023-2028) & (US$ Million)
Table 70. Europe Vaccine Particulate Adjuvants Sales by Company (2017-2022) & (K Pcs)
Table 71. Europe Vaccine Particulate Adjuvants Sales Market Share by Company (2017-2022)
Table 72. Europe Vaccine Particulate Adjuvants Revenue by Company (2017-2022) & (US$ Million)
Table 73. Europe Vaccine Particulate Adjuvants Revenue Market Share by Company (2017-2022)
Table 74. Europe Vaccine Particulate Adjuvants Sales by Type (2017-2022) & (K Pcs)
Table 75. Europe Vaccine Particulate Adjuvants Sales by Type (2023-2028) & (K Pcs)
Table 76. Europe Vaccine Particulate Adjuvants Revenue by Type (2017-2022) & (US$ Million)
Table 77. Europe Vaccine Particulate Adjuvants Revenue by Type (2023-2028) & (US$ Million)
Table 78. Europe Vaccine Particulate Adjuvants Sales by Application (2017-2022) & (K Pcs)
Table 79. Europe Vaccine Particulate Adjuvants Sales by Application (2023-2028) & (K Pcs)
Table 80. Europe Vaccine Particulate Adjuvants Revenue by Application (2017-2022) & (US$ Million)
Table 81. Europe Vaccine Particulate Adjuvants Revenue by Application (2023-2028) & (US$ Million)
Table 82. Europe Vaccine Particulate Adjuvants Sales by Country (2017-2022) & (K Pcs)
Table 83. Europe Vaccine Particulate Adjuvants Sales by Country (2023-2028) & (K Pcs)
Table 84. Europe Vaccine Particulate Adjuvants Revenue by Country (2017-2022) & (US$ Million)
Table 85. Europe Vaccine Particulate Adjuvants Revenue by Country (2023-2028) & (US$ Million)
Table 86. Asia Pacific Vaccine Particulate Adjuvants Sales by Company (2017-2022) & (K Pcs)
Table 87. Asia Pacific Vaccine Particulate Adjuvants Sales Market Share by Company (2017-2022)
Table 88. Asia Pacific Vaccine Particulate Adjuvants Revenue by Company (2017-2022) & (US$ Million)
Table 89. Asia Pacific Vaccine Particulate Adjuvants Revenue Market Share by Company (2017-2022)
Table 90. Asia Pacific Vaccine Particulate Adjuvants Sales by Type (2017-2022) & (K Pcs)
Table 91. Asia Pacific Vaccine Particulate Adjuvants Sales by Type (2023-2028) & (K Pcs)
Table 92. Asia Pacific Vaccine Particulate Adjuvants Revenue by Type (2017-2022) & (US$ Million)
Table 93. Asia Pacific Vaccine Particulate Adjuvants Revenue by Type (2023-2028) & (US$ Million)
Table 94. Asia Pacific Vaccine Particulate Adjuvants Sales by Application (2017-2022) & (K Pcs)
Table 95. Asia Pacific Vaccine Particulate Adjuvants Sales by Application (2023-2028) & (K Pcs)
Table 96. Asia Pacific Vaccine Particulate Adjuvants Revenue by Application (2017-2022) & (US$ Million)
Table 97. Asia Pacific Vaccine Particulate Adjuvants Revenue by Application (2023-2028) & (US$ Million)
Table 98. Asia Pacific Vaccine Particulate Adjuvants Sales by Region (2017-2022) & (K Pcs)
Table 99. Asia Pacific Vaccine Particulate Adjuvants Sales by Region (2023-2028) & (K Pcs)
Table 100. Asia Pacific Vaccine Particulate Adjuvants Revenue by Region (2017-2022) & (US$ Million)
Table 101. Asia Pacific Vaccine Particulate Adjuvants Revenue by Region (2023-2028) & (US$ Million)
Table 102. Latin America Vaccine Particulate Adjuvants Sales by Company (2017-2022) & (K Pcs)
Table 103. Latin America Vaccine Particulate Adjuvants Sales Market Share by Company (2017-2022)
Table 104. Latin America Vaccine Particulate Adjuvants Revenue by Company (2017-2022) & (US$ Million)
Table 105. Latin America Vaccine Particulate Adjuvants Revenue Market Share by Company (2017-2022)
Table 106. Latin America Vaccine Particulate Adjuvants Sales by Type (2017-2022) & (K Pcs)
Table 107. Latin America Vaccine Particulate Adjuvants Sales by Type (2023-2028) & (K Pcs)
Table 108. Latin America Vaccine Particulate Adjuvants Revenue by Type (2017-2022) & (US$ Million)
Table 109. Latin America Vaccine Particulate Adjuvants Revenue by Type (2023-2028) & (US$ Million)
Table 110. Latin America Vaccine Particulate Adjuvants Sales by Application (2017-2022) & (K Pcs)
Table 111. Latin America Vaccine Particulate Adjuvants Sales by Application (2023-2028) & (K Pcs)
Table 112. Latin America Vaccine Particulate Adjuvants Revenue by Application (2017-2022) & (US$ Million)
Table 113. Latin America Vaccine Particulate Adjuvants Revenue by Application (2023-2028) & (US$ Million)
Table 114. Latin America Vaccine Particulate Adjuvants Sales by Country (2017-2022) & (K Pcs)
Table 115. Latin America Vaccine Particulate Adjuvants Sales by Country (2023-2028) & (K Pcs)
Table 116. Latin America Vaccine Particulate Adjuvants Revenue by Country (2017-2022) & (US$ Million)
Table 117. Latin America Vaccine Particulate Adjuvants Revenue by Country (2023-2028) & (US$ Million)
Table 118. Middle East and Africa Vaccine Particulate Adjuvants Sales by Company (2017-2022) & (K Pcs)
Table 119. Middle East and Africa Vaccine Particulate Adjuvants Sales Market Share by Company (2017-2022)
Table 120. Middle East and Africa Vaccine Particulate Adjuvants Revenue by Company (2017-2022) & (US$ Million)
Table 121. Middle East and Africa Vaccine Particulate Adjuvants Revenue Market Share by Company (2017-2022)
Table 122. Middle East and Africa Vaccine Particulate Adjuvants Sales by Type (2017-2022) & (K Pcs)
Table 123. Middle East and Africa Vaccine Particulate Adjuvants Sales by Type (2023-2028) & (K Pcs)
Table 124. Middle East and Africa Vaccine Particulate Adjuvants Revenue by Type (2017-2022) & (US$ Million)
Table 125. Middle East and Africa Vaccine Particulate Adjuvants Revenue by Type (2023-2028) & (US$ Million)
Table 126. Middle East and Africa Vaccine Particulate Adjuvants Sales by Application (2017-2022) & (K Pcs)
Table 127. Middle East and Africa Vaccine Particulate Adjuvants Sales by Application (2023-2028) & (K Pcs)
Table 128. Middle East and Africa Vaccine Particulate Adjuvants Revenue by Application (2017-2022) & (US$ Million)
Table 129. Middle East and Africa Vaccine Particulate Adjuvants Revenue by Application (2023-2028) & (US$ Million)
Table 130. Middle East and Africa Vaccine Particulate Adjuvants Sales by Country (2017-2022) & (K Pcs)
Table 131. Middle East and Africa Vaccine Particulate Adjuvants Sales by Country (2023-2028) & (K Pcs)
Table 132. Middle East and Africa Vaccine Particulate Adjuvants Revenue by Country (2017-2022) & (US$ Million)
Table 133. Middle East and Africa Vaccine Particulate Adjuvants Revenue by Country (2023-2028) & (US$ Million)
Table 134. Brenntag Biosector (Denmark) Corporation Information
Table 135. Brenntag Biosector (Denmark) Description and Overview
Table 136. Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2017-2022)
Table 137. Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Product and Services
Table 138. Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants SWOT Analysis
Table 139. Brenntag Biosector (Denmark) Recent Developments
Table 140. CSL Limited (Australia) Corporation Information
Table 141. CSL Limited (Australia) Description and Overview
Table 142. CSL Limited (Australia) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2017-2022)
Table 143. CSL Limited (Australia) Vaccine Particulate Adjuvants Product and Services
Table 144. CSL Limited (Australia) Vaccine Particulate Adjuvants SWOT Analysis
Table 145. CSL Limited (Australia) Recent Developments
Table 146. SEPPIC (France) Corporation Information
Table 147. SEPPIC (France) Description and Overview
Table 148. SEPPIC (France) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2017-2022)
Table 149. SEPPIC (France) Vaccine Particulate Adjuvants Product and Services
Table 150. SEPPIC (France) Vaccine Particulate Adjuvants SWOT Analysis
Table 151. SEPPIC (France) Recent Developments
Table 152. Agenus, Inc (US) Corporation Information
Table 153. Agenus, Inc (US) Description and Overview
Table 154. Agenus, Inc (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2017-2022)
Table 155. Agenus, Inc (US) Vaccine Particulate Adjuvants Product and Services
Table 156. Agenus, Inc (US) Vaccine Particulate Adjuvants SWOT Analysis
Table 157. Agenus, Inc (US) Recent Developments
Table 158. Novavax, Inc (US) Corporation Information
Table 159. Novavax, Inc (US) Description and Overview
Table 160. Novavax, Inc (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2017-2022)
Table 161. Novavax, Inc (US) Vaccine Particulate Adjuvants Product and Services
Table 162. Novavax, Inc (US) Vaccine Particulate Adjuvants SWOT Analysis
Table 163. Novavax, Inc (US) Recent Developments
Table 164. SPI Pharma, Inc (US) Corporation Information
Table 165. SPI Pharma, Inc (US) Description and Overview
Table 166. SPI Pharma, Inc (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2017-2022)
Table 167. SPI Pharma, Inc (US) Vaccine Particulate Adjuvants Product and Services
Table 168. SPI Pharma, Inc (US) Vaccine Particulate Adjuvants SWOT Analysis
Table 169. SPI Pharma, Inc (US) Recent Developments
Table 170. Invivogen (US) Corporation Information
Table 171. Invivogen (US) Description and Overview
Table 172. Invivogen (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (U